You are here: Industry Insights > BMS

News List

US judge orders BMS, Sanofi to pay $834m for illegal marketing of Plavix pharmaceutical-technology
February 18, 2021
US Judge Dean Ochiai has ordered Bristol-Myers Squibb (BMS) and Sanofi to pay over $834m to the state of Hawaii for illegally marketing their blood-thinning drug Plavix.
BMS’ deucravacitinib beats Otezla in psoriasis study pharmatimes
February 05, 2021
Bristol Myers Squibb’s investigative drug deucravacitinib has demonstrated positive results in a Phase III trial, including showing superiority over Amgen’s Otezla (apremilast).
NICE recommends Revlimid for newly diagnosed multiple myeloma patients pharmatimes
January 27, 2021
Bristol Myers Squibb’s (BMS) Revlimid (lenalidomide) has received a recommendation from the UK’s National Institute of Health and Care Excellence (NICE) for newly diagnosed multiple myeloma patients.
NICE no for BMS’ multiple sclerosis drug Zeposia pharmatimes
January 25, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s (BMS) Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS).
NICE no for BMS’ Opdivo for head and neck cancer pharmatimes
January 11, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has turned down Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based ...
EMA launches review of BMS’ Opdivo for oesophageal cancer pharmatimes
January 06, 2021
The European Medicines Agency (EMA) has launched its centralized review process for Bristol Myers Squibb’s Opdivo (nivolumab) as an adjuvant treatment for oesophageal or gastroesophageal junction (GEJ) cancer.
Evotec, BMS Advance Targeted Protein Degradation Projects contractpharma
December 18, 2020
The first two targets transition into drug discovery after completing a comprehensive target validation process.
EC approves Opdivo for treatment of oesophageal squamous cell carcinoma europeanpharmaceuticalreview
November 27, 2020
The European Commission has approved Opdivo (nivolumab) to treat oesophageal squamous cell carcinoma after studies showed its clinical benefits compared to chemotherapy alone.
BMS inks drug discovery deal with Schrödinger pharmatimes
November 25, 2020
Bristol Myers Squibb will pay $55m upfront to American life sciences company Schrödinger to access its drug discovery platform.
BMS acquires biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
November 19, 2020
Bristol Myers Squibb (BMS) has completed its acquisition of clinical-stage biopharma firm MyoKardia in an all-cash transaction for $13.1bn.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page